On this page you will find our recommendations sorted by BNF chapter.
Appraisal Reports are available to stakeholders on request.
Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on email@example.com
|Anti-vascular endothelial growth factor therapies (bevacizumab or ranibizumab) as an adjunct to vitrectomy in diabetic retinopathy (NETAG)||Recommendation||Not recommended||07/07/2009|
|Bevacizumab (Avastin®) for age-related macular degeneration (Updated)||Recommendation||Recommended as an option||09/09/2014|
|Bevacizumab (Avastin®) for diabetic macular oedema (NETAG)||Recommendation||Not recommended||10/07/2012|
|Bevacizumab (Avastin®) for neovascular glaucoma secondary to central retinal vein occlusion (NETAG)||Recommendation||Not recommended||12/04/2011|
|Bevacizumab (Avastin®) or ranibizumab (Lucentis®) for macular oedema secondary to retinal vein occlusion(s)(NETAG)||Recommendation||Bevacizumab (Avastin®) 1.25 mg using a ‘when required’ (PRN) regimen is recommended for management of macular oedema secondary to retinal vein occlusion||18/01/2011|
|Bevacizumab (Avastin®) or ranibizumab (Lucentis®) for non-AMD choriodal neovascular disease (NETAG)||Recommendation Treatment guidelines||Recommends bevacizumab intravitreal injection using a ‘when required’ dose regimen for the treatment of non-AMD CNV, as described in the North East Retinal Group treatment guideline||08/10/2009|
|High dose multivitamins and minerals for the prevention of progression of age-related macular degeneration||Recommendation||Not recommended||03/06/2014|
|Intraocular telescope by VisionCare™ for age-related macular degeneration (NETAG)||Recommendation||Not recommended||13/11/2012|
|Sequential pharmacological therapies in the management of macular oedema secondary to retinal vein occlusion||Recommendation RVO treatment pathway||Recommended||09/09/2014|
|Verteporfin (Visudyne®) with photo-dynamic therapy for chronic central serous chorioretinopathy||Updated recommendation||Recommended||02/06/2020|